Press release
SANOFI LICENSES WORLDWIDE RIGHTS ON REGENERATIVE TREATMENT FOR OSTEOARTHRITIS AND CARTLAGE DISORDERS FROM SCIL TECHNOLOGY
Martinsried, Germany, December 20, 2011 – Scil Technology GmbH, a privately held biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that Sanofi (EURONEXT: SAN and NYSE: SNY) has exclusively licensed Scil Technology’s program for the regenerative treatment of osteoarthritis and cartilage disorders.Under the agreement, SCIL Technology will receive an upfront payment and potential milestone payments totaling up to EUR 180 million. Moreover, the company is entitled to receive undisclosed royalties on worldwide product sales. Sanofi will assume responsibility for the progression of the development program with immediate effect, including the start of clinical trials.
The program is based on targets for the regeneration of cartilage tissue, which also stimulate chondrocyte differentiation and the synthesis of cartilage matrix. The leading compound is based on a proprietary formulation for direct delivery into the joint, making it an excellent treatment option for osteoarthritis. The program is currently in advanced preclinical development.
“We are very pleased about the agreement with Sanofi,” said Christian Nafe, CEO of Scil Technology. “It underlines the success of our development programs and our unique expertise in combining biologics with special formulations to develop innovative biopharmaceutical products.”
"Sanofi's profound expertise in the therapeutic area and the professional interaction we had during the whole process make us confident, that Sanofi is the right partner we could find for this program" said Klaus Binder, COO of Scil Technology.
“Osteoarthritis is a painful and disabling disease that affects millions of patients. At present there is no available therapy that has been proven to impact the progressive joint damage that is associated with the disease,” said John Alam, Head of Therapeutic Strategic Unit (TSU) - Aging, Global Research & Development, Sanofi. “Scil Technology’s cartilage regenerative program brings an innovative approach to Sanofi’s osteoarthritis portfolio that we believe may have promise to address progressive joint damage by targeting the activation of the body’s internal mechanism of cartilage repair and regeneration.”
The cartilage regenerative program is Scil Technology’s second program which has been out-licensed successfully. The first (GDF-5) was taken over by Medtronic after completion of Phase II.
###
About Scil Technology GmbH
Scil Technology is a privately held German biopharmaceutical company highly experienced in the development of biopharmaceutical drugs with special know-how in demanding formulations. Its development expertise encompasses medical devices, pharmaceutical drugs and regenerative medical products.
Scil Technology, a wholly owned subsidiary of BioNet Holding GmbH, is located in Martinsried, Germany. For further information please visit: http://www.sciltechnology.com
Contact:
Scil Technology GmbH
Fraunhoferstr. 15
82152 Martinsried
Germany
Iris Margraf
Director Business Development
Tel.: +49/89/8565-1800
Fax: +49/89/8565-1818
Email: Info@sciltechnology.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SANOFI LICENSES WORLDWIDE RIGHTS ON REGENERATIVE TREATMENT FOR OSTEOARTHRITIS AND CARTLAGE DISORDERS FROM SCIL TECHNOLOGY here
News-ID: 204834 • Views: …
More Releases from Scil Technology GmbH
Nanohale AG acquires R&D and service units of Scil Technology GmbH
- Transaction creates new Nanohale subsidiary named Formycon GmbH -
Dortmund and Martinsried, Germany, January 9, 2012 – Scil Technology GmbH and Nanohale AG today announced that Nanohale has acquired the entire R&D, contract development and manufacturing organization of Scil Technology GmbH in an asset deal, effective December 31, 2011. Employees and inventory of Scil Technology GmbH have become part of Formycon GmbH, a fully-owned subsidiary of Nanohale AG. The rights…
More Releases for Sanofi
Prostate Cancer Market 2032 Astellas, AstraZeneca plc, Johnson & Johnson, Sanofi …
The global prostate cancer market is poised to grow at an exponential pace, primarily due to the mounting prevalence of prostate cancer, rapidly aging population and strong bolstering pipeline. The market would undergo a transformation during the analysis period, attributed by emerging product launches and line extensions opted for existing therapies. Limited treatment options along with a booming patient pool has generated the need for novel effective therapies with enhanced…
Therapeutic BCG Vaccines market: Key Market Developments and Innovations in 2022 …
"
The Therapeutic BCG Vaccines global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key…
Vaccine Market 2021 Analysis by Global Manufacturers - GlaxoSmithKline plc, Merc …
The Vaccine Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Vaccine market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the Vaccine market. Importantly, it allows players to gain deep insights into the business development…
Travelers Vaccines Market 2027: Top Players & COVID-19 Impact Analysis - Merck , …
Travelers Vaccines Market Reports presents an in-depth assessment of this report including market drivers, challenges, enabling technologies, vertical market opportunities, applications, key trends, standardization, opportunities, future roadmap, value chain, ecosystem player profiles and strategies.
The report mainly studies the size, recent trends and development status of the Travelers Vaccines market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement…
Global Freeze-Dried BCG Vaccine Market 2020 - Merck, Sanofi Pasteur (Sanofi), Ja …
Goble Freeze-Dried BCG Vaccine Market 2020, Market Size Value CAGR (USD Million)and revenue ($$$) for the historical period (2016 - 19) and projected years (2020 - 26), SWOT, Industry, Sales, Demand, Analysis, Opportunities and Forecast to 2026 All Cover in This Report
Freeze-Dried BCG Vaccine
View Detailed Report at @ http://www.marketresearchstore.com/report/global-freeze-dried-bcg-vaccine-market-professional-survey-618056
Market study on most trending report Global global Freeze-Dried BCG Vaccine Market 2020 Industry Research Report detailed information on…
Immense Growth In Isoproterenol Market Trends and Global Overview | Sanofi Avent …
The 'Global Isoproterenol Industry, 2014-2024 Market Research Report' is a professional and in-depth study on the current state of the Global Isoproterenol Market with a focus on the market conditions. The report provides key statistics on the market status of the Isoproterenol manufacturer and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry…
